July 2023
Starting Aug. 15, we’ll require prior authorization for some diabetes drugs
Beginning Aug. 15, 2023, health care providers for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members will need to obtain prior authorization to show that the brand-name medications listed below are being used for Type 2 diabetes for us to pay for them. Medicare members are excluded from this change.
Brand-name medication |
FDA-approved indication |
Plan payment requirement |
Bydureon®
Byetta®
Mounjaro®
Ozempic®Rybelsus®
Trulicity®
Victoza® |
Type 2 diabetes |
Payment from Blue Cross or BCN will require one of the following:
- Being used for the treatment of Type 2 diabetes
- Trial of one generic or preferred medication for the treatment of Type 2 diabetes
|
Members should ask their prescribing doctor to contact us to request a prior authorization for the medications listed above. If the prescription isn’t authorized in advance, it may not be paid for.
We announced a similar change on Feb. 1, 2023, which didn’t apply to members who were already taking these medications. Effective Aug. 15, all members are required to have a prior authorization for these medications.
Providers can request prior authorization electronically. For information on how to submit the request:
- Go to ereferrals.bcbsm.com.
- Click on Blue Cross for commercial members or BCN for BCN members.
- Click on Pharmacy Benefit Drugs on the left.
For a complete list of drugs and associated requirements, go to bcbsm.com/druglists. |